Volume 15, Issue 4, Pages (April 2014)

Slides:

Advertisements

Similar presentations

Volume 14, Issue 12, Pages (November 2013)

Advertisements

Volume 370, Issue 9586, Pages (August 2007)

Volume 14, Issue 4, Pages (April 2013)

Volume 17, Issue 12, Pages (December 2016)

Volume 16, Issue 2, Pages (February 2015)

Volume 359, Issue 9322, Pages (June 2002)

Volume 12, Issue 11, Pages (October 2011)

Volume 376, Issue 9747, Pages (October 2010)

Volume 16, Issue 9, Pages (September 2015)

Volume 15, Issue 6, Pages (May 2014)

Volume 17, Issue 2, Pages (February 2016)

Stephen Ansell, MD, PhD Mayo Clinic

Volume 14, Issue 4, Pages (April 2013)

Volume 377, Issue 9783, Pages (June 2011)

Volume 13, Issue 12, Pages (December 2012)

Volume 389, Issue 10076, Pages (April 2017)

Volume 371, Issue 9611, Pages (February 2008)

Volume 9, Issue 5, Pages (May 2008)

Volume 14, Issue 3, Pages (March 2013)

Volume 15, Issue 4, Pages (April 2014)

Volume 15, Issue 4, Pages (April 2014)

Volume 376, Issue 9757, Pages (December 2010)

Volume 14, Issue 12, Pages (December 2015)

Volume 14, Issue 10, Pages (September 2013)

Volume 373, Issue 9663, Pages (February 2009)

Volume 14, Issue 7, Pages (June 2013)

Volume 15, Issue 4, Pages (April 2014)

Volume 9, Issue 10, Pages (October 2008)

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim.

Volume 12, Issue 7, Pages (July 2011)

Volume 4, Issue 6, Pages (June 2017)

Volume 18, Issue 3, Pages (March 2017)

Volume 379, Issue 9812, Pages (January 2012)

Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label,

Volume 13, Issue 12, Pages (December 2012)

Volume 6, Issue 6, Pages (June 2005)

Volume 14, Issue 6, Pages (May 2013)

Volume 11, Issue 4, Pages (April 2010)

Volume 20, Issue 1, Pages (January 2019)

Volume 373, Issue 9666, Pages (March 2009)

Volume 18, Issue 3, Pages (March 2017)

Volume 385, Issue 9962, Pages (January 2015)

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled,

Volume 19, Issue 4, Pages (April 2018)

Volume 15, Issue 8, Pages (July 2014)

Volume 373, Issue 9676, Pages (May 2009)

Volume 18, Issue 8, Pages (August 2017)

Volume 378, Issue 9786, Pages (July 2011)

Volume 15, Issue 6, Pages (May 2014)

Volume 381, Issue 9880, Pages (May 2013)

Volume 14, Issue 6, Pages (May 2013)

Volume 13, Issue 11, Pages (November 2012)

Volume 5, Issue 4, Pages (April 2018)

Volume 375, Issue 9726, Pages (May 2010)

Volume 16, Issue 8, Pages (August 2015)

Volume 19, Issue 10, Pages (October 2018)

Volume 15, Issue 6, Pages (May 2014)

Volume 15, Issue 1, Pages (January 2014)

Volume 15, Issue 8, Pages (July 2014)

Volume 11, Issue 1, Pages (January 2010)

Volume 376, Issue 9757, Pages (December 2010)

Volume 18, Issue 10, Pages (October 2017)

Volume 375, Issue 9715, Pages (February 2010)

Volume 376, Issue 9747, Pages (October 2010)

Volume 14, Issue 9, Pages (August 2013)

Volume 13, Issue 7, Pages (July 2014)

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

Volume 20, Issue 5, Pages (May 2019)

Volume 14, Issue 7, Pages (June 2013)

Volume 17, Issue 2, Pages (February 2016)

Presentation transcript:

Volume 15, Issue 4, Pages 424-435 (April 2014) Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial Dr Kirit M Ardeshna, FRCP, Wendi Qian, PhD, Paul Smith, MSc, Nivette Braganca, MSc, Lisa Lowry, FRCPath, Pip Patrick, PhD, June Warden, MSc, Lindsey Stevens, Christopher F E Pocock, PhD, Fiona Miall, MD, Prof David Cunningham, FMedSci, John Davies, FRCP, Andrew Jack, FRCP, Richard Stephens, MA, Jan Walewski, MD, Prof Burhan Ferhanoglu, MD, Prof Ken Bradstock, PhD, Prof David C Linch, FMedSci The Lancet Oncology Volume 15, Issue 4, Pages 424-435 (April 2014) DOI: 10.1016/S1470-2045(14)70027-0 Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile On Sept 30, 2007, recruitment into the rituximab induction group was closed and the study was amended to a two-arm study. *Inclusive of the patients enrolled in the three-arm study (83 in the watch and wait group and 85 in the maintenance rituximab group). The Lancet Oncology 2014 15, 424-435DOI: (10.1016/S1470-2045(14)70027-0) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 2 Kaplan-Meier curves for the two-arm study (A) Time to start of new treatment, (B) progression-free survival, (C) overall survival, and (D) time to histological transformation. HR=hazard ratio. The Lancet Oncology 2014 15, 424-435DOI: (10.1016/S1470-2045(14)70027-0) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 3 Kaplan-Meier curves for the 252 patients randomly assigned in the initial three-arm study (A) Time to start of new treatment, (B) progression-free survival, (C) overall survival, and (D) time to histological transformation. HR=hazard ratio. The Lancet Oncology 2014 15, 424-435DOI: (10.1016/S1470-2045(14)70027-0) Copyright © 2014 Elsevier Ltd Terms and Conditions